

Substitute for form 1449A/PTO  
**INFORMATION DISCLOSURE  
 STATEMENT BY APPLICANT**  
 (Use as many sheets as necessary)



PTO/SB/08A(10-01)  
 Approved for use through 10/31/2002, OMB 65-1-0031  
 US Patent & Trademark Office, U.S. DEPARTMENT OF COMMERCE  
 Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known

Application Number	10/723,423
Filing Date	November 26, 2003
First Named Inventor	Jensen, Gerard
Group Art Unit	1615
Examiner Name	Unknown

Sheet 1 of 2

Attorney Docket No: 1992.005US1

**US PATENT DOCUMENTS**

Examiner Initial *	USP Document Number	Publication Date	Name of Patentee or Applicant of cited Document	Filing Date If Appropriate
h	US-4,145,410	03/20/1979	Sears, Barry D.	06/17/1997
	US-4,224,179	09/23/1980	Schneider, Michel	09/23/1980
	US-4,235,871	11/25/1980	Papahadjopoulos, Demetrios P., et al.	02/24/1978
	US-4,522,803	06/11/1985	Lenk, Robert P., et al.	03/24/1983
	US-4,588,578	05/13/1986	Fountain, Michael W., et al.	08/08/1983
	US-4,753,788	06/28/1988	Gamble, Ronald C.	01/31/1985
	US-4,946,683	08/07/1990	Forssen, Eric A.	08/04/1989
	US-5,077,056	12/31/1991	Bally, M. B., et al.	12/12/1988
	US-5,316,771	05/31/1994	Barenholz, Yechezkel, et al.	12/18/1992
	US-5,380,531	01/10/1995	Chakrabarti, Ajoy, et al.	06/02/1992
	US-5,795,589	08/18/1998	Mayer, Lawrence D., et al.	02/05/1997
	US-5,814,335	09/29/1998	Webb, Murray S., et al.	09/17/1997
h	US-6,083,530	07/04/2000	Mayer, Lawrence D., et al.	05/26/1998

**FOREIGN PATENT DOCUMENTS**

Examiner Initials *	Foreign Document No	Publication Date	Name of Patentee or Applicant of cited Document	T <sup>2</sup>
h	EP-0546951A1	06/16/1993	Ostro, Marc J.	
	EP-0719546A1	07/03/1996	Bally, Marcel B., et al.	
	WO-03041682A3	05/22/2003	Webb, Murray, et al.	
h	WO-9913816A2	03/25/1999	Moynihan, Karen L., et al.	

**OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
h		ADLAKHA-HUTCHEON, G., et al., "Controlled destabilization of a liposomal drug delivery system enhances mitoxantrone antitumor activity", <u>Nature Biotechnology</u> , 17(8), (August 1999), 775-779	
		BANDAK, S., et al., "Pharmacological studies of cisplatin encapsulated in long-circulating liposomes in mouse tumor models", <u>Anticancer Drugs</u> , 10, (November 10, 1999), 911-920	
		COLBERN, C. T., et al., "Antitumor activity of Herceptin in combination with STEALTH liposomal cisplatin or nonliposomal cisplatin in a HER2 positive human breast cancer model", <u>Journal of Inorganic Biochemistry</u> , 77(1-2), (October 1999), 117-120	
h		DEMARIO, M. D., et al., "A Phase I Study of Liposome-Formulated Cisplatin (SPI-77 R) Given Every 3 Weeks in Patients With Advanced Cancer", <u>Proceedings of ASCO</u> , Vol. 17, <a href="http://www.asco.org/ac/1,1003,12-002643-00_18-0031-00_19-006314,00.asp">http://www.asco.org/ac/1,1003,12-002643-00_18-0031-00_19-006314,00.asp</a> , (1998), Abstract 883	

EXAMINER

*Kishu*

DATE CONSIDERED

3/2/07

Substitute Disclosure Statement Form (PTO-1449)  
 \* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 600. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. \* Applicant's unique citation designation number (optional) \* Applicant is to place a check mark here if English language Translation is attached

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

**Complete if Known**

Application Number	10/723,423
Filing Date	November 26, 2003
First Named Inventor	Jensen, Gerard
Group Art Unit	1615
Examiner Name	Unknown

Sheet 2 of 2

Attorney Docket No: 1992.005US1

**OTHER DOCUMENTS – NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
lw		HARRINGTON, K. J., et al., "Phase I-II study of pegylated liposomal cisplatin (SPI-077) in patients with inoperable head and neck cancer", <u>Annals of Oncology</u> , 12(4), (April 2001),493-496	
		HONG, R L., et al., "Direct comparison of liposomal doxorubicin with or without polyethylene glycol coating in C-26 tumor-bearing mice is surface coating with polyethylene glycol beneficial?", <u>Clinical Cancer Research</u> , 5(11), (November 1999),3645-3652	
		LIM, H. J., et al., "Influence of drug release characteristics on the therapeutic activity of liposomal mitoxantrone", <u>The Journal of Pharmacology and Experimental Therapeutics</u> , 281(1), (April 1997),566-573	
		MEERUM TERWOGT, J. M., et al., "Phase I and pharmacokinetic study of SPI-77, a liposomal encapsulated dosage form of cisplatin", <u>Cancer Chemotherapy and Pharmacology</u> , 49(3), (March 2002),201-210	
		NEWMAN, M. S., et al., "Comparative pharmacokinetics, tissue distribution, and therapeutic effectiveness of cisplatin encapsulated in long-circulating, pegylated liposomes (SPI-077) in tumor-bearing mice", <u>Cancer Chemotherapy and Pharmacology</u> , 43(1), Erratum in <u>Cancer Chemotherapy and Pharmacology</u> , 43(6), 524 (attached to downloaded document),(1999),1-7	
		VEAL, G. J., et al., "A phase I study in paediatric patients to evaluate the safety and pharmacokinetics of SPI-77, a liposome encapsulated formulation of cisplatin", <u>British Journal of Cancer</u> , 84(8), (April 2001),1029-1035	
lw		WORKING, P. K., et al., "Comparative intravenous toxicity of cisplatin solution and cisplatin encapsulated in long-circulating, pegylated liposomes in cynomolgus monkeys", <u>Toxicological Sciences</u> , 46(1), (November 1998),155-165	

EXAMINER


Kube

DATE CONSIDERED

3/7/07

Substitute Disclosure Statement Form (PTO-1449)

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 909. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. \* Applicant's unique citation designation number (optional) 2 Applicant is to place a check mark here if English language Translation is attached



Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
 STATEMENT BY APPLICANT**  
 (Use as many sheets as necessary)

Under the Paperwork Reduction Act of 1995, no person is required to respond to a collection of information unless it carries a valid OMB control number.

Complete if Known	
Application Number	10/723,423
Filing Date	November 26, 2003
First Named Inventor	Jensen, Gerard
Group Art Unit	1615
Examiner Name	Unknown
Sheet 1 of 1	
Attorney Docket No: 1992.005US1	

**US PATENT DOCUMENTS**

Examiner Initial *	USP Document Number	Publication Date	Name of Patentee or Applicant of cited Document	Class	Subclass	Filing Date If Appropriate
h	US-3,993,754	11/23/1976	Rahman, Yueh-Erh, et al.	514	12	10/09/1974
	US-4,885,172	12/05/1989	Bally, M. B., et al.	424	417	12/15/1986
	US-4,938,949	07/03/1990	Borch, Richard F., et al.	514	476	09/12/1988
h	US-5,616,341	04/01/1997	Mayer, L. D., et al.	424	450	08/26/1993

**FOREIGN PATENT DOCUMENTS**

Examiner Initials *	Foreign Document No	Publication Date	Name of Patentee or Applicant of cited Document	Class	Subclass	T <sup>2</sup>
h	EP-0290296A2	11/09/1988	Bally, M. B., et al.	A61K	9/50	
	WO-0105372A2	01/25/2001	Abra, R. M., et al.	A61K	9/00	
	WO-8601102A1	02/27/1986	Bally, Marcel B., et al.	A61K	9/60	
h	WO-9202244A1	02/20/1992	Chakrabarti, A., et al.	A61K	37/22	

**OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
---------------------	----------------------	---	----------------

EXAMINER

Kush

DATE CONSIDERED

3/7/07

Substitute Disclosure Statement Form (PTO-1449)

\* EXAMINER: Initial if reference considered, whether or not citation is to conform with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional) 2 Applicant is to place a check mark here if English language Translation is attached